Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Drug development of MET inhibitors: targeting oncogene addiction and expedience.

Comoglio PM, Giordano S, Trusolino L.

Nat Rev Drug Discov. 2008 Jun;7(6):504-16. doi: 10.1038/nrd2530. Review.

PMID:
18511928
2.

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.

Christensen JG, Burrows J, Salgia R.

Cancer Lett. 2005 Jul 8;225(1):1-26. Epub 2004 Nov 11. Review.

PMID:
15922853
3.

Hepatocyte growth factor, its receptor, and their potential value in cancer therapies.

Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, Nakamura T.

Crit Rev Oncol Hematol. 2005 Jan;53(1):35-69. Review.

PMID:
15607934
4.

Molecular cancer therapy: can our expectation be MET?

Migliore C, Giordano S.

Eur J Cancer. 2008 Mar;44(5):641-51. doi: 10.1016/j.ejca.2008.01.022. Epub 2008 Mar 4. Review.

PMID:
18295476
5.

Targeting the MET oncogene in cancer and metastases.

Stella GM, Benvenuti S, Comoglio PM.

Expert Opin Investig Drugs. 2010 Nov;19(11):1381-94. doi: 10.1517/13543784.2010.522988. Epub 2010 Sep 26. Review.

6.

c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.

Sattler M, Salgia R.

Curr Oncol Rep. 2007 Mar;9(2):102-8. Review.

PMID:
17288874
7.

Targeting the c-MET signaling pathway for cancer therapy.

Liu X, Yao W, Newton RC, Scherle PA.

Expert Opin Investig Drugs. 2008 Jul;17(7):997-1011. doi: 10.1517/13543784.17.7.997 . Review.

PMID:
18549337
8.

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.

Eder JP, Vande Woude GF, Boerner SA, LoRusso PM.

Clin Cancer Res. 2009 Apr 1;15(7):2207-14. doi: 10.1158/1078-0432.CCR-08-1306. Epub 2009 Mar 24. Review.

9.

Showering c-MET-dependent cancers with drugs.

Knudsen BS, Vande Woude G.

Curr Opin Genet Dev. 2008 Feb;18(1):87-96. doi: 10.1016/j.gde.2008.02.001. Epub 2008 Apr 9. Review.

PMID:
18406132
10.

Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.

Matsumoto K, Nakamura T, Sakai K, Nakamura T.

Proteomics. 2008 Aug;8(16):3360-70. doi: 10.1002/pmic.200800156. Review.

PMID:
18646008
11.

Progress in cancer therapy targeting c-Met signaling pathway.

Jung KH, Park BH, Hong SS.

Arch Pharm Res. 2012 Mar;35(4):595-604. doi: 10.1007/s12272-012-0402-6. Epub 2012 May 3. Review.

PMID:
22553051
12.

Targeting the HGF/c-Met axis: state of play.

Yap TA, de Bono JS.

Mol Cancer Ther. 2010 May;9(5):1077-9. doi: 10.1158/1535-7163.MCT-10-0122. Epub 2010 May 4. Review. No abstract available.

13.

Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.

Liu X, Newton RC, Scherle PA.

Trends Mol Med. 2010 Jan;16(1):37-45. doi: 10.1016/j.molmed.2009.11.005. Epub 2009 Dec 22. Review.

PMID:
20031486
14.

HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.

Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, Shah M, Christensen JG, Rosen N, Solit DB, Weiser MR.

Mol Cancer Ther. 2008 Nov;7(11):3499-508. doi: 10.1158/1535-7163.MCT-08-0374. Epub 2008 Oct 30.

15.

Small molecule c-Met kinase inhibitors: a review of recent patents.

Porter J.

Expert Opin Ther Pat. 2010 Feb;20(2):159-77. doi: 10.1517/13543770903514137. Review.

PMID:
20100000
16.

Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.

Toschi L, Jänne PA.

Clin Cancer Res. 2008 Oct 1;14(19):5941-6. doi: 10.1158/1078-0432.CCR-08-0071. Review.

17.

The biological role of HGF-MET axis in tumor growth and development of metastasis.

Lesko E, Majka M.

Front Biosci. 2008 Jan 1;13:1271-80. Review.

PMID:
17981628
18.

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy.

Weinstein IB, Joe AK.

Nat Clin Pract Oncol. 2006 Aug;3(8):448-57. Review.

PMID:
16894390
19.

Multifaceted targeting in cancer: the recent cell death players meet the usual oncogene suspects.

Drosopoulos K, Pintzas A.

Expert Opin Ther Targets. 2007 May;11(5):641-59. Review.

PMID:
17465723
20.

Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.

Albrecht BK, Harmange JC, Bauer D, Berry L, Bode C, Boezio AA, Chen A, Choquette D, Dussault I, Fridrich C, Hirai S, Hoffman D, Larrow JF, Kaplan-Lefko P, Lin J, Lohman J, Long AM, Moriguchi J, O'Connor A, Potashman MH, Reese M, Rex K, Siegmund A, Shah K, Shimanovich R, Springer SK, Teffera Y, Yang Y, Zhang Y, Bellon SF.

J Med Chem. 2008 May 22;51(10):2879-82. doi: 10.1021/jm800043g. Epub 2008 Apr 22.

PMID:
18426196

Supplemental Content

Support Center